Last reviewed · How we verify
TJ202, Lenalidomide and Dexamethasone
Lenalidomide is an immunomodulatory drug that stimulates the immune system to attack cancer cells, while dexamethasone is a corticosteroid that has anti-inflammatory and immunosuppressive properties.
Lenalidomide is an immunomodulatory drug that stimulates the immune system to attack cancer cells, while dexamethasone is a corticosteroid that has anti-inflammatory and immunosuppressive properties. Used for Multiple myeloma, Mantle cell lymphoma.
At a glance
| Generic name | TJ202, Lenalidomide and Dexamethasone |
|---|---|
| Sponsor | TJ Biopharma Co., Ltd. |
| Drug class | Immunomodulator |
| Target | Cereblon |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide works by binding to cereblon, a protein that regulates the activity of other proteins involved in the immune response. This binding leads to the degradation of certain proteins that promote the growth and survival of cancer cells. Dexamethasone, on the other hand, has a broad range of effects on the immune system, including the suppression of inflammation and the modulation of immune cell activity.
Approved indications
- Multiple myeloma
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |